Semaglutide Use Linked to Erythromelalgia Remission

Case details diagnostic workup and rapid symptom resolution following GLP-1 receptor agonist initiation.

By
Kathryn Wighton
April 22, 2026
4 min

MDSpire News

Objective:

To report a case of complete remission of erythromelalgia symptoms following treatment with semaglutide, highlighting its potential significance in treatment options.

Key Findings:

Complete remission of erythromelalgia symptoms was achieved after starting semaglutide, with symptoms resolving before significant weight loss.
The patient's BMI decreased from 33.9 kg/m² to 23.2 kg/m² over 15 months.
Normal nerve fiber density and absence of thermal allodynia argued against small-fiber neuropathy.

Interpretation:

The rapid resolution of symptoms suggests a pharmacologic effect of semaglutide rather than solely weight loss, indicating a need for further research into its mechanisms.

Limitations:

Causality cannot be established from a single case.
Retrospective assessment and absence of validated pain scoring.
Lack of continuous perfusion or temperature monitoring, emphasizing the uniqueness of this case.

Conclusion:

This case represents the first documented instance of erythromelalgia remission following GLP-1 receptor agonist therapy, warranting further investigation into their role in neurovascular pain syndromes and potential therapeutic applications.